| 29.19 0.79 (2.78%) | 10-30 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 34.15 | 1-year : | 39.88 |
| Resists | First : | 29.23 | Second : | 34.15 |
| Pivot price | 28.12 |
|||
| Supports | First : | 26.2 | Second : | 24.32 |
| MAs | MA(5) : | 28.26 |
MA(20) : | 27.84 |
| MA(100) : | 27.96 |
MA(250) : | 24.5 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 69.8 |
D(3) : | 60.8  |
| RSI | RSI(14): 62 |
|||
| 52-week | High : | 33.06 | Low : | 16.1 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ PGNY ] has closed below upper band by 8.5%. Bollinger Bands are 35.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 29.26 - 29.38 | 29.38 - 29.5 |
| Low: | 28.07 - 28.19 | 28.19 - 28.31 |
| Close: | 28.99 - 29.2 | 29.2 - 29.42 |
Progyny, Inc. functions as a benefits management corporation, dedicated to providing specialized solutions for fertility and broader family-building initiatives to employers throughout the United States. Its core fertility offering is characterized by a distinctive benefits plan architecture, paired with personalized, white-glove member support services and access to a meticulously chosen network of top-tier fertility specialists. Additionally, the company presents Progyny Rx, an all-encompassing pharmacy benefits solution that ensures its members can readily acquire the essential medications for their treatments. Moreover, Progyny facilitates employer-sponsored reimbursement programs to support surrogacy and adoption journeys. The company, which was established in 2008 and has its main offices in New York City, previously operated as Auxogyn, Inc. before adopting the Progyny, Inc. moniker in 2015.
Fri, 30 Oct 2026
Progyny’s (PGNY) Full-Year Guidance Lowered on Utilization Headwinds - Yahoo Finance
Fri, 30 Oct 2026
Progyny Inc (NASDAQ:PGNY): Strong Growth With a Bull Flag Technical Setup - ChartMill
Thu, 29 Oct 2026
Progyny, Inc. (PGNY) stock price, news, quote and history - Yahoo Finance Australia
Wed, 28 Oct 2026
Progyny, Inc. (PGNY) Stock Forecasts - Yahoo Finance
Wed, 21 Oct 2026
Progyny, Inc. Announces Details for Its Third Quarter 2026 Results Report - Yahoo Finance
Wed, 07 Oct 2026
Progyny, Inc. Selling Season Pacing to Record Level, Revealing Critical Insights on Latest Market Dynamics - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Plans
|
|
| Shares Out | 77 (M) |
| Shares Float | 70 (M) |
| Held by Insiders | 1.9 (%) |
| Held by Institutions | 109.2 (%) |
| Shares Short | 5,090 (K) |
| Shares Short P.Month | 4,450 (K) |
| EPS | 0.92 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.9 |
| Profit Margin | 6 % |
| Operating Margin | 11.4 % |
| Return on Assets (ttm) | 10.1 % |
| Return on Equity (ttm) | 16.2 % |
| Qtrly Rev. Growth | 5.3 % |
| Gross Profit (p.s.) | 4.19 |
| Sales Per Share | 17.07 |
| EBITDA (p.s.) | 1.63 |
| Qtrly Earnings Growth | 78.9 % |
| Operating Cash Flow | 201 (M) |
| Levered Free Cash Flow | 196 (M) |
| PE Ratio | 31.72 |
| PEG Ratio | 0 |
| Price to Book value | 4.94 |
| Price to Sales | 1.7 |
| Price to Cash Flow | 11.12 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|